In conclusion, our study provided real-world clinical evidence that patients with EGFR-mutated NSCLC, particularly those who progressed from previous generations of EGFR TKI, had better clinical outcome and significantly longer survival outcome with osimertinib treatment. Here, EGFR is linked to non-small cell lung carcinoma.